We partner with countries and work at the global level to assess supply and demand for health products and build markets that address the five A’s: affordability, availability, assured quality, appropriate design, and awareness.
At PATH, we connect local innovators and decision-makers with our global network of partners to develop responsive, human-centered solutions to health challenges.
A new initiative led by PATH in partnership with John Snow, Inc., the DMPA-SC Access Collaborative works with ministries of health and partners to strengthen scale-up and build a robust global market for DMPA-SC, as an important new addition to the full range of contraceptive options.
The DMPA-SC Evidence to Practice workshop was held in May 2018 with the goal of increasing voluntary and high-quality access to DMPA-SC within a wide range of contraceptive methods.
Several thousands of health workers around the world have been trained to safely provide DMPA-SC injections in clinics, community locations, and villages, and even to support women to self-inject.
Family planning advocates can ensure that a country’s policies and funding promote access to all contraceptive options, so women can make an informed and voluntary choice. The Advocacy Pack for Subcutaneous DMPA was designed for advocates around the globe to help increase access to this new injectable contraceptive option.
Research in Uganda and elsewhere has shown that women are able to self-administer DMPA-SC safely and effectively, that they like doing so, and that self-injection helps support women to continue using injectable contraception.